Context Therapeutics Inc.
No enriched coverage for $CNTX in the last 7 days.
No SEC Form 4 filings for $CNTX in the last 30 days.
See all $CNTX insider activity →Context Therapeutics Inc. (NASDAQ: CNTX) said Nasdaq notified it on July 29, 2026 that it failed to meet the $1.00 minimum bid price for 30 straight business days under Nasdaq Rule 5550(a)(2). The notice has no immediate trading impact. The company has until Jan. 25, 2027 to regain compliance, with possible extension and delisting risk.
Context Therapeutics (Nasdaq: CNTX) said it granted a non-qualified stock option inducement award to a new employee for 146,000 shares under Nasdaq Listing Rule 5635(c)(4). Granted July 7, 2026 at an exercise price of $0.70 per share. Options expire in 10 years and vest over four years.
Context Therapeutics (Nasdaq: CNTX) said it was added to the Russell 2000 and Russell 3000 indexes effective June 26, 2026 close. The Russell 3000 covers about 98% of the investable U.S. equity market; Russell 2000 is its small-cap subset. The change may affect index-fund and benchmark tracking.
Recent CNTX coverage spans financial news, corporate actions and market movers.
The filing discloses a concrete listing-risk timeline that can pressure the stock via liquidity and delisting fears, especially if the bid price stays below $1.
This is a routine equity inducement grant with no stated financial guidance impact, but it confirms ongoing hiring and dilution mechanics at a specific strike price.
Index inclusion can drive near-term buying from passive funds and rebalancing trades, but it is not a fundamental change.
Index inclusion can drive mechanical buying from Russell-tracking funds and raise near-term demand for CNTX shares.
Share-authorizations expand potential dilution capacity, which can pressure valuation if future financings are expected.
alphai scores every news story that mentions CNTX with an AI model for sentiment and relevance, and aggregates insider trades from Context Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Context Therapeutics Inc. (NASDAQ: CNTX) said Nasdaq notified it on July 29, 2026 that it failed to meet the $1.00 minimum bid price for 30 straight business days under Nasdaq Rule 5550(a)(2). The notice has no immediate trading impact. The company has until Jan. 25, 2027 to regain compliance, with possible extension and delisting risk.
2 min readContext Therapeutics (Nasdaq: CNTX) said it granted a non-qualified stock option inducement award to a new employee for 146,000 shares under Nasdaq Listing Rule 5635(c)(4). Granted July 7, 2026 at an exercise price of $0.70 per share. Options expire in 10 years and vest over four years.
2 min readContext Therapeutics (Nasdaq: CNTX) said it was added to the Russell 2000 and Russell 3000 indexes effective June 26, 2026 close. The Russell 3000 covers about 98% of the investable U.S. equity market; Russell 2000 is its small-cap subset. The change may affect index-fund and benchmark tracking.
2 min readContext Therapeutics (NASDAQ:CNTX) shares rose 2.7% after hours after the company was added to the Russell 2000 and Russell 3000 indexes, effective June 26, 2026 close, according to Investing.com. The change may increase institutional buying as index funds rebalance. Russell 3000 covers ~98% of investable U.S. equities; Russell 2000 is the small-cap subset.
3 min readContext Therapeutics Inc. (CNTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cntx-20260624 0001842952 FALSE 12/31 0001842952 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
3 min readMaxim Group cut its price target for Context Therapeutics (NASDAQ:CNTX) from $8.00 to $4.00 in a Tuesday report, while keeping a “buy” rating, according to Benzinga. The target implies 490.84% upside vs. the stock’s current ~$0.68. Other analysts cited mixed views, with a MarketBeat consensus “Moderate Buy” and $6.17 target.
4 min readContext Therapeutics (CNTX) reported interim Phase 1 results for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer. As of May 29, 2026, at active doses of 140–280µg, 29% (2/7) of evaluable patients had confirmed partial responses and 57% (4/7) had disease control; some maintained benefit for 6+ months. CRS was Grade 1 in 11% of ovarian patients. The Phase 1a dose-escalation enrolled 21 patients; the 560µg dose was not advanced. CNTX plans Q3W dosing in 2H 2026 and Phase 1b in 2027.
4 min readContext Therapeutics (Nasdaq: CNTX) said it granted a non-qualified stock option to a new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The award covers 146,000 shares, granted June 8, 2026 at an exercise price of $1.71 per share. Options expire in 10 years and vest over four years.
2 min readContext Therapeutics (CNTX) has adopted significant shareholder-friendly board governance changes following a Delaware Court of Chancery ruling. Effective March 11, 2026, director terms will be one year, and directors can be removed with or without cause by a majority vote, replacing previous three-year terms and removal for cause only. The company's 2026 annual meeting on June 24, 2026, will reflect these changes, emphasizing increased investor influence, though TipRanks’ AI Analyst, Spark, rates CNTX as Neutral due to weak financial performance despite a strong technical uptrend.
3 min readContext Therapeutics Inc. (NASDAQ:CNTX) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $5.40. The company's stock is currently trading around $1.12, reflecting its early-stage biopharma status and recent Q3 EPS miss. Institutional investors, including Vanguard Group Inc., hold approximately 14% of the shares.
4 min read
